NCT05773768

Brief Summary

In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,300

participants targeted

Target at P75+ for not_applicable atrial-fibrillation

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 17, 2023

Completed
1 year until next milestone

Study Start

First participant enrolled

March 28, 2024

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

December 13, 2024

Status Verified

December 1, 2024

Enrollment Period

1.8 years

First QC Date

February 15, 2023

Last Update Submit

December 9, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Identification and management of risk factors and comorbidities

    The number of risk factors and comorbidities that are identified and for which treatment is initiated during base mapping and at the end of the randomized controlled trial.

    6 months

Secondary Outcomes (6)

  • AF symptom burden

    6 months

  • Quality of life (QoL)

    6 months

  • Referrals to other disciplines

    6 months

  • Patient and health care provider satisfaction

    6 months

  • Healthcare resource use/costs

    6 months

  • +1 more secondary outcomes

Study Arms (2)

New care program

EXPERIMENTAL

The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.

Device: EHRA-PATHS software tool

Routine clinical care

NO INTERVENTION

The health care provider follows current clinical practice with regards to history taking, physical examination etc.

Interventions

Newly developed care pathways integrated into a care-management software tool

New care program

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Newly diagnosed atrial fibrillation (paroxysmal, persistent or permanent)
  • ≥65 years of age
  • Willing and able to participate and to attend the scheduled follow-up visits.

You may not qualify if:

  • Atrial fibrillation episode was due to a trigger (i.e. postoperative, infection, hyperthyroidism etc.)
  • Life expectancy of less than 1 year
  • Participation in another clinical study (registry studies not included)
  • Severe cognitive impairment / dementia (defined based on MMSE and CDR scoring systems)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Groningen

Groningen, Netherlands

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2023

First Posted

March 17, 2023

Study Start

March 28, 2024

Primary Completion

January 1, 2026

Study Completion

January 1, 2026

Last Updated

December 13, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations